Evidence map›Paper›PMID 39462036›Full record

SynthesisMolecular psychiatry2025

Association of the GRIK4 rs1954787 polymorphism with clinical response in antidepressant-treated depressed patients: results from a prospective cohort and meta-analysis.

Kenneth Chappell, Romain Colle, Khalil El Asmar, Florence Gressier, Jérôme Bouligand, Séverine Trabado, Bruno Fève, Laurent Becquemont, Emmanuelle Corruble, Céline Verstuyft

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kenneth ChappellMOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.
Romain ColleMOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.ORCID 0000-0002-2549-4495
Khalil El AsmarMOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.ORCID 0000-0002-6030-8088
Florence GressierMOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.ORCID 0000-0002-5160-9823
Jérôme BouligandService de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Paris, F-94275, France.
Séverine TrabadoService de Génétique Moléculaire, Pharmacogénétique et Hormonologie de Bicêtre, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Paris, F-94275, France.
Bruno FèveSorbonne Université-INSERM UMR_S938, Centre de Recherche Saint-Antoine, Institut Hospitalo-Universitaire ICAN, Service d'Endocrinologie, CRMR PRISIS, Hôpital Saint-Antoine, Assistance Publique-Hôpitaux de Paris, Paris, F-75012, France.
Laurent BecquemontMOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.ORCID 0000-0003-3477-8956
Emmanuelle Corruble *MOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.
Céline Verstuyft *MOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France. celine.verstuyft@aphp.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Genetic factors influence the effect of its main treatment option, antidepressant drugs (ATD). The GRIK4 rs1954787(T>C) genetic polymorphism was associated with response following 1-3 months of ATD treatment in some studies, but not others. We aimed to analyze its association with clinical outcomes in a cohort of 6-month ATD-treated patients and meta-analysis. Clinical data were obtained at baseline and after 1 (M1), 3 (M3), and 6 (M6) months of ATD treatment in 390 patients of the METADAP cohort. Mixed-effects models were used to assess the association of the GRIK4 rs1954787 polymorphism with the Hamilton Depression Rating Scale (HDRS) score and response and remission rates across time. Meta-analyses of ATD treatment response were performed with previously meta-analyzed data and METADAP. Compared to C allele carriers at M3 (n = 200), TT homozygotes at M3 (n = 66) had higher HDRS scores (coef = 3.37, 95% CI [1.30-5.54], P

Indexed as

Antidepressive AgentsKainic Acid ReceptorsMajor Depressive DisorderAdultAllelesCohort StudiesFemaleGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideProspective StudiesTreatment OutcomeAntidepressive AgentsGRIK4 protein, humanKainic Acid Receptors

Identifiers

PMID39462036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.